AI Article Synopsis
- Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children, with uveitis being the leading extra-articular issue that can cause vision problems.
- JIA-associated uveitis (JIA-U) poses significant challenges for pediatricians and ophthalmologists due to its subtle onset and the risk of serious complications affecting vision.
- Current treatments begin with topical glucocorticoids, followed by methotrexate and newer biological drugs that specifically target disease mechanisms, greatly improving outcomes for those who do not respond to traditional therapies.
Article Abstract
Juvenile idiopathic arthritis (JIA) is the most frequent rheumatic disease of childhood and uveitis is its most common extra-articular manifestation. JIA-associated uveitis (JIA-U) is one of the main causes of visual impairment in children and represents a major challenge for pediatrician and ophthalmologist, due to its insidious onset and sight-threatening complications. Topical glucocorticoids are the first line of treatment, followed by conventional disease-modifying anti-rheumatic drugs (DMARDs), usually methotrexate (MTX). In recent years, new biological drugs targeting specific molecules involved in disease pathogenesis, have significantly improved the prognosis of the disease, especially for cases refractory to conventional therapies. In this review we discuss the role of biological agents in JIA-U, focusing on cytokine blockers and cell-targeted therapies aimed to control ocular inflammation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182104 | PMC |
| http://dx.doi.org/10.3389/fopht.2022.954901 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!